Search | Page 8 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. How we treat higher-risk myelodysplastic syndromes

    ... is less than 6 months, and consideration should be given to clinical trials. Higher-risk eligible patients should be offered consultation ... therapy, induction chemotherapy or a clinical trial should be considered to prevent disease progression, although the ...

    Research Article last updated 01/08/2014 - 8:57am.

  2. Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?

    ... and lenalidomide both have meaningful single-agent clinical activity in HR-MDS and AML with del(5q). Early-phase trials in HR-MDS ... In this article, we review the results of a Phase I trial of a sequential azacitidine-lenalidomide combination approach in patients ...

    Research Article last updated 06/28/2013 - 1:24pm.

  3. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia

    ... peripheral-blood lymphocytes and is preferred in other clinical circumstances. METHODS: From December 2005 through July 2010, we performed a randomized trial comparing these two ATG formulations in conventional regimens. Patients ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes.

    ... and the malignant clone . A recent Phase I trial testing the lenalidomide and azacitidine combination yielded encouraging ... addition of lenalidomide to azacitidine provides additional clinical benefit over azacitidine monotherapy. ...

    Research Article last updated 10/11/2011 - 5:58pm.

  5. An update on the treatment of myelodysplastic syndromes.

    ... , are approved for intermediate-2- and high-risk MDS. Trial results have increased the understanding of these treatments, alone or ... often requires at least three to six months to achieve a clinical response. In the meantime, or in addition to active therapy, ...

    Research Article last updated 10/11/2011 - 5:58pm.

  6. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes.

    ... BACKGROUND: In the AZA-001 trial, azacitidine (75 mg/m(2)/d subcutaneously for Days 1-7 of every ... category in 48% of patients, and therefore may enhance clinical benefit in patients with higher-risk MDS. ...

    Research Article last updated 10/11/2011 - 5:58pm.

  7. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial.

    ... Decitabine given on a 5-day schedule provided meaningful clinical benefit for patients with MDS, with more than half demonstrating ...

    Research Article last updated 10/11/2011 - 5:58pm.

  8. MEDALIST Trial

    For more details on this clinical trial, including contact information, please see this trial’s listing on ... for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements. This is a Phase ...

    Clinical Trial last updated 02/22/2017 - 11:42am.

  9. Treatments

    ... cure".   Clinical Trials ... you may want to consider taking part in a clinical trial , also called a research study. ...

    Topic section last updated 02/16/2017 - 3:04pm.

  10. A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation

    For more details on this clinical trial, including contact information, please see this trial’s listing on ... evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an ...

    Clinical Trial last updated 02/22/2017 - 11:21am.